Frontiers in Psychiatry
August 6, 2025
Grace Blest‐hopley, Giuseppe Pasculli, Simon Ruffell et al.
3 citations
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effects, promoting neuroplasticity and reorganising functional connectivity across cortical and subcortical networks involved in emotion and cognition. Veterans with traumatic brain injuries (TBI) often experience chronic neurological and psychological...
Pharmacological Research
September 1, 2024
Giorgia Caspani, Simon Ruffell, WaiFung Tsang et al.
13 citations
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...
Drug Science, Policy and Law
2024
Simon Ruffell, Sam Gandy, WaiFung Tsang et al.
10 citations
Indigenous Amazonian shamanic ayahuasca practice is embedded in a nature-based context and is employed as an ecological mediating agent and in collective environmental decision-making processes by some of the groups that use it. Phenomenologically, the ayahuasca experience is often rich in nature-based themes and content, and its usage has been associated with eliciting shifts in perspectives...
Psychiatry and Clinical Neurosciences Reports
December 1, 2023
Simon Ruffell, Max Crosland-Wood, Rob Palmer et al.
37 citations
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There...
Frontiers in Psychiatry
2023
Simon Ruffell, Nige Netzband, WaiFung Tsang et al.
1 citation
correction
[This corrects the article DOI: 10.3389/fpsyt.2021.687615.].
Drug Science, Policy and Law
2023
WaiFung Tsang, Simon Ruffell, Nigel Netzband et al.
Background The potential benefits of ayahuasca on mental health conditions are well documented. This pilot study is the first to explore whether there is an association with ayahuasca use and reductions in inattention, hyperactivity and impulsivity, the core features of attention-deficit/hyperactivity disorder. Methods In this exploratory, observational pilot study, the Adult...
Frontiers in Psychiatry
June 9, 2021
Simon Ruffell, Nige Netzband, WaiFung Tsang et al.
74 citations
Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took...
Psychopharmacology
July 23, 2020
Nige Netzband, Simon Ruffell, Sabriya Linton et al.
56 citations
Abstract Abstract Ayahuasca is a psychoactive plant brew containing dimethyltryptamine (DMT) and monoamine oxidase inhibitors (MAOIs). It originates from the Amazon basin, where it is used primarily for ceremonial purposes. Ayahuasca tourists are now entering certain communities seeking alternative physical or psychological healing, as well as spiritual growth. Rationale Recent evidence has...